A Phase 2 interventional study of Adaptive radiotherapy in Diffuse Glioma, Glioblastoma and Adaptive Radiotherapy, sponsored by Tata Memorial Centre. Recruiting at 1 site in India. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Tata Memorial Centre · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Glioblastoma with a site in India — 3 open to participants now, 3 under way, none of them phase 3. Glioblastoma · India.
Among the 15 studies in Glioblastoma with a site in India, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 2, and was the 14th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →3 of the 15 studies in Glioblastoma with a site in India are open now. Recruiting first, the newest first:
Tata Memorial Centre · Sites in India
Ages 18–70
All India Institute of Medical Sciences, Bhubaneswar · Sites in India
Ages 18+
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 88 across the 12 interventional studies, 150 across the 3 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 10 most frequent:
Tata Memorial Centre is the lead sponsor of 64 studies on the registry; 42 are open to participants now.
Tata Memorial Centre has 2 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Glioblastoma with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics. The common types of diffuse gliomas include glioblastoma, astrocytoma, and oligodendroglioma. The standard treatment for diffuse gliomas includes surgery followed by radiation and chemotherapy. As per standard institutional practice, a uniform dose of radiation is delivered to the disease area and MRI is done before and after the treatment. In this study, MRI and PET scan will be done before starting the treatment and standard dose of radiation will be delivered. The interval imaging will be done twice during the course of treatment with MRI and PET, followed by dose modifications. The CT, MRI, and PET will be combined. Based on PET imaging, specific dose will be altered and delivered to specific areas. Dose modification will be done with the help of artificial intelligence. Participant's assessment will be done at regular intervals.
Modifications in radiation plans are done based on the changes in disease seen in scans is likely to improve the accuracy of RT treatments. Dose modifications based on imaging to resistant areas will help achieve better tumor control, reduce treatment-related toxicities, precise delivery of the RT and adjusting doses to the organs at risk (OAR) and changes in disease leading to better treatment compliance. Creating an artificial intelligence framework in radiation oncology promises to improve quality of workflow, treatment planning and RT delivery.
The aim of the study is to develop an artificial intelligence workflow for treatment of glioma with adaptive radiotherapy. This study will be conducted in Tata Memorial Centre on a population of 60 patients for a duration of 2 years. The total study duration is 4 years.
Glioblastoma multiforme (GBM) represents grade 4 diffuse gliomas accounting for the most common primary malignant central nervous system (CNS) tumors in adults . GBM is treated with radiotherapy (RT) and concurrent chemotherapy following maximal safe resection, with a median survival of approximately 15-18 months . GBM harbors significant intratumoral heterogeneity with areas of multiclonal and hypoxic areas rendering higher chances of disease relapse following standard RT .
Similarly, distinct compartments can be well appreciated on magnetic resonance imaging (MRI): enhancing tumor core (TC) with central necrotic areas and the peritumoral region (PTR), which consists of microscopic tumor infiltration and vasogenic edema . Similar to regions of radioresistant areas within the TC, the microscopic disease in the PTR plays a vital role in disease relapse . Other grade 2 and 3 diffuse gliomas include isocitrate dehydrogenase (IDH) mutant astrocytoma and oligodendroglioma . In the recent World Health Organization (WHO) classification of CNS tumors, molecular information is combined with histopathological information for integrated classification. IDH-wildtype tumors are further molecularly characterized and considered as GBM since the prognosis is shown to be dismal. Oligodendrogliomas are confirmed based on the presence of deletion of 1p19q chromosomal arms. Grade 2/3 diffuse gliomas are typically seen as tumors with T2-weighted hyperintense tumors. The treatment is similar to GBM, with maximal safe resection followed by radiation and concurrent and adjuvant chemotherapy.
Radiotherapy for Diffuse Gliomas Radiotherapy (RT) forms an integral role in the multimodality management of diffuse gliomas . Radiation is indicated in low-grade gliomas with high-risk features or high-grade gliomas following maximal safe resection . The radiation (RT) in diffuse gliomas in GBM is delivered using conformal techniques to the residual disease and cavity, called the gross tumor volume (GTV). The surrounding area is included in the clinical target volume (CTV) to treat areas of microscopic disease. For GBM, an expansion of 1.5 -2 cm is done from the GTV, which is identified as an enhancing area on T1c sequences to include areas of PTR (T2w hyperintensity) and edited from anatomical barriers like meninges and dural reflections . For IDH-mutant gliomas, the residual tumor and cavity (identified as T2w hyperintensity region) are included as GTV and further expansion of 5-10 mm is done to be included as CTV . The standard practice involves delivering a uniform dose of radiation to the planning target volume (PTV), which encompasses an isotropic margin expansion surrounding the CTV to account for set-up uncertainties. In GBM and IDHmutant high-grade astrocytoma, the total dose of 59.4-60 Gy is delivered over 6-7 weeks with 1.8-2 Gy per fraction. A relatively lower dose of radiation, in the range of 54.0-59.4 Gy, is delivered over 6-7 weeks using 1.8-2 Gy per fraction for oligodendrogliomas. As per the current paradigm, radiation is planned on computed tomography (CT) for dose computation and MRI for visualization of target volumes and organs at risk (OAR), done once before treatment, based on which fractionated radiation is delivered over 6- 7 weeks. Recent evidence with MRI undertaken during the course of treatment has demonstrated the changes in dynamics of the residual disease, surgical cavity, and also the OARs in a proportion of patients, suggesting that treatment is delivered based on imaging at a single time-point can lead to inaccuracies .Therefore, adaptive radiotherapy (ART) to modify radiation plans based on the spatial changes of the target volume and OAR is likely to improve the accuracy of RT treatments. Also, serial imaging during treatment can be used to identify areas of tumor or PTR showing refractory disease or vasogenic edema, with provisions for biological modifications of RT doses . The use of conformal radiation techniques like intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) can enable delivery of differential radiation doses precisely to different areas of the target volume, known as dose painting .Positron Emission Tomography (PET) Functional imaging with positron emission tomography (PET) has attained wide popularity in oncology in disease staging, identifying hypoxic areas, and guiding radiation planning . For gliomas, amino acid PET like O-(2-[18F] fluoroethyl) -L-tyrosine (FET) or Fluorodopa (F-DOPA) has been proven effective with areas of a higher tumor to white matter ratio, suggestive areas of active disease (19) . The use of PET scans during treatment can help identify areas refractory to RT, reflected by higher uptake of the radioisotope. Higher doses to such regions provide a window for biological adaption and can potentially improve control rates. Similarly, quantitative analysis of imaging (more popularly known as radiomics) can help differentiate areas of microscopic tumor from vasogenic edema in the PTR, which otherwise appears similar to conventional imaging . Artificial Intelligence The role of artificial intelligence in oncology is increasingly recognized, ranging from optimization of healthcare resource utilization and decision-making to quantitative image analysis for prognostication and the potential ability to serve as a noninvasive biomarker . The practice of contemporary radiation oncology heavily relies on the interaction of humans and machines in almost every treatment planning process, including contouring of target volumes, OAR, treatment-planning processes, and during treatment delivery. Creating an artificial intelligence framework in radiation oncology promises to improve workflow efficiency and accuracy and enable treatment planning and delivery rapidly and efficiently. The use of adaptive radiotherapy will be further facilitated using machine learning algorithms with appropriate identification of patients to be benefitted from volumetric or biological adaptation, autosegmentation of target/OAR, automated treatment planning, and biological modification based on spatial and temporal changes of quantitative imaging parameters. Standard institutional practice The standard institutional practice includes a dose of 59.4 Gy in 33 fractions over 6.5 weeks for patients with glioblastoma and 55.8 Gy in 31 fractions over 6 weeks for patients with oligodendroglioma. Concurrent temozolomide is used for all patients undergoing radiation at the dose of 75 mg/m 2 of body surface area during the course of radiation with weekly monitoring on blood counts. All radiation treatments are planned based on single time CT and MRI scan without any scheduled interval scans during radiation, and no adaptation is done. Adjuvant chemotherapy with temozolomide is started after 4 weeks of radiation completion at dose of 150 mg/m 2 for five days and repeated on monthly basis and dose escalated to 200 mg/m 2 if tolerating well and normal blood counts. As standard practice 6 and 12 cycles of temozolomide are scheduled for GBM and IDH-mutant glioma (astrocytoma and oligodendroglioma) respectively. After treatment completion clinical follow-up is scheduled every 3-6 months in the first 2 years and thereafter every 6-12 months for all the patients. Surveillance imaging is scheduled every 6-12 months in the first 5 years and thereafter on annual basis or interval imaging undertaken as prompted clinically.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age: 18-70 years. Performance Scale (KPS) ≥60
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adaptive radiotherapy
Radiation: Adaptive radiotherapy
Adaptive radiotherapy
Radiation: Adaptive radiotherapy
Volumetric and biological adaptive radiotherapy will be delivered based on interval imaging with MRI and PET scan during treatment.
Proportion of patients undergoing volumetric and biological adaptation. Cumulative rate of symptomatic radionecrosis (RN) at 2 years.
Proportion of patients where modification of radiation plan was done.
Time frame: 2 years
Cumulative rate of symptomatic radionecrosis at 2 years
Patients developing symptomatic radionecerosis will be analyzed using Kaplan-Meier survival method.
Time frame: 4 years
Progression free survival
Progression free survival will be analyzed using Kaplan Meier method.
Time frame: 4 years
Overall survival
Overall survival will be analyzed using Kaplan Meier method.
Time frame: 4 years
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.
Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 24 months is below that.
Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tata Memorial Centre